PNEUMOVAX, solution injectable en seringue préremplie. Vaccin pneumococcique polyosidique

solution injectable · intramusculaire / sous-cutanée

Directory source checks passedOriginal source language: French

Source data retrieved: 2026-09-17. Clinical review is not yet available.

Formsolution injectable

Routeintramusculaire / sous-cutanée

Ingredient entries23

CountryFrance

Product identity

At a glance

Authorisation holder: MSD FRANCE
Authorisation status: Autorisation active
Market status: Commercialisée
Country: France
Source reference: CIS 60614280

Reported market status does not confirm current pharmacy stock.

From the official composition record

Ingredients & strength

Source entries are shown individually. An active substance (SA) and its reference moiety (FT) may describe the same ingredient; do not add their strengths together.

Source composition entries for PNEUMOVAX, solution injectable en seringue préremplie. Vaccin pneumococcique polyosidique
Ingredient	Strength / reference	Source role
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 23F (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 22
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 10A (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 11
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 6B (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 6
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 33F (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 23
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 14 (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 14
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 1 (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 1
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 22F (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 21
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 19A (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 18
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 3 (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 3
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 19F (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 19
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 20 (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 20
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 7F (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 7
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 8 (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 8
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 15B (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 15
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 18C (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 17
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 12F (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 13
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 5 (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 5
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 4 (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 4
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 9N (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 9
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 17F (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 16
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 11A (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 12
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 2 (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 2
STREPTOCOCCUS PNEUMONIAE SÉROTYPE 9V (POLYOSIDES DE)solution	25 microgrammesune dose de 0,5 ml	SAGroup 10

Pack references

Presentations (1)

1 seringue(s) préremplie(s) en verre de 0,5 ml avec 2 aiguille(s)

CIP13 3400930044384

Présentation active · Déclaration de commercialisation

From the French medicines authority

Official documents

The official product entry provides access to the patient leaflet and professional product information when available. Documents are in French and availability varies by medicine.

Open the official product entryBDPM · CIS 60614280 · Opens in a new tab

Check the medicine name, strength and form against your pack. The authority’s current documents may be newer than the catalogue snapshot shown here.

Where this information comes from

Sources & dates

Base de données publique des médicaments (BDPM), France. Retrieval dates record when we obtained the source files; they are not clinical review dates or a guarantee of current stock.

Source files and their retrieval dates
Source file	Retrieved	Source file modified
fr_products.txt	2026-09-17	Not supplied
fr_composition.txt	2026-09-17	Not supplied
fr_packs.txt	2026-09-17	Not supplied

Directory source checks cover the factual catalogue record.Molindra clinical guidance has not yet been reviewed or published for this medicine.

Our sources and review process →